These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 30322215)

  • 1. Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?
    Lambert M; Capuano V; Olschewski A; Sabourin J; Nagaraj C; Girerd B; Weatherald J; Humbert M; Antigny F
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30322215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of ion channels in pulmonary arterial hypertension.
    Guibert C; Marthan R; Savineau JP
    Curr Pharm Des; 2007; 13(24):2443-55. PubMed ID: 17692012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Store-Operated Ca
    Masson B; Montani D; Humbert M; Capuano V; Antigny F
    Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension.
    Santos-Gomes J; Le Ribeuz H; Brás-Silva C; Antigny F; Adão R
    Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
    Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F
    Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension.
    Le Ribeuz H; Capuano V; Girerd B; Humbert M; Montani D; Antigny F
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32882918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ion channels as convergence points in the pathology of pulmonary arterial hypertension.
    Jouen-Tachoire TRH; Tucker SJ; Tammaro P
    Biochem Soc Trans; 2021 Aug; 49(4):1855-1865. PubMed ID: 34346486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ion channels and transporters as therapeutic targets in the pulmonary circulation.
    Olschewski A; Papp R; Nagaraj C; Olschewski H
    Pharmacol Ther; 2014 Dec; 144(3):349-68. PubMed ID: 25108211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacological treatment of pulmonary arterial hypertension.
    Frumkin LR
    Pharmacol Rev; 2012 Jul; 64(3):583-620. PubMed ID: 22659328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension.
    Redel-Traub G; Sampson KJ; Kass RS; Bohnen MS
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potassium channels in pulmonary arterial hypertension.
    Boucherat O; Chabot S; Antigny F; Perros F; Provencher S; Bonnet S
    Eur Respir J; 2015 Oct; 46(4):1167-77. PubMed ID: 26341985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin antagonism in pulmonary arterial hypertension.
    Lee SH; Channick RN
    Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension.
    Bonnet S; Archer SL
    Pharmacol Ther; 2007 Jul; 115(1):56-69. PubMed ID: 17583356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Heterozygous
    Bohnen MS; Roman-Campos D; Terrenoire C; Jnani J; Sampson KJ; Chung WK; Kass RS
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28889099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.
    Oishi P; Datar SA; Fineman JR
    Expert Opin Pharmacother; 2011 Aug; 12(12):1845-64. PubMed ID: 21609302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ORAI Channels as Potential Therapeutic Targets in Pulmonary Hypertension.
    Rode B; Bailey MA; Marthan R; Beech DJ; Guibert C
    Physiology (Bethesda); 2018 Jul; 33(4):261-268. PubMed ID: 29897302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension.
    Moudgil R; Michelakis ED; Archer SL
    Microcirculation; 2006 Dec; 13(8):615-32. PubMed ID: 17085423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies.
    Jasińska-Stroschein M; Orszulak-Michalak D
    Pharmacol Rep; 2014 Aug; 66(4):552-64. PubMed ID: 24948054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient Receptor Potential Channel 4 Encodes a Vascular Permeability Defect and High-Frequency Ca(2+) Transients in Severe Pulmonary Arterial Hypertension.
    Francis M; Xu N; Zhou C; Stevens T
    Am J Pathol; 2016 Jun; 186(6):1701-9. PubMed ID: 27083517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.
    Vaidya B; Gupta V
    J Control Release; 2015 Aug; 211():118-33. PubMed ID: 26036906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.